All practice questions

4736 questions

All types4,736 Multiple choice2,413 Multiple select567 Numeric127 Matching858 Ordering771

A 62-year-old man comes to the clinic for a routine follow-up. He has a history of type 2 diabetes mellitus, hyperlipidemia, and hypertension. His current medications include metformin, atorvastatin, lisinopril, and amlodipine. He brings a magazine advertisement for a newly approved adjunctive cardiovascular medication, 'Lipozon,' which claims to 'reduce the risk of major adverse cardiovascular events (MACE) by 33%!'

The physician reviews the FDA package insert and the pivotal randomized controlled trial (RCT) summary provided in the literature.

Study Parameter	Lipozon + Standard Therapy (n=3000)	Placebo + Standard Therapy (n=3000)
5-Year MACE Incidence	4.0%	6.0%
ALT/AST > 3x ULN	2.5%	0.5%
CYP3A4 Inhibition	Strong	None

The patient's recent laboratory results show an AST of 32 U/L and ALT of 35 U/L (both within normal limits). He asks if he should add this medication to his regimen.

Based on the provided literature data and the patient's medical history, which of the following is the most appropriate recommendation regarding the addition of this medication?

Advise adding the medication because the 33% absolute risk reduction provides a substantial clinical benefit that outweighs the slight increase in transaminases

Advise adding the medication because only 3 patients need to be treated to prevent one major adverse cardiovascular event

Advise adding the medication but closely monitor liver enzymes, as the absolute risk reduction of 2% justifies its use despite the increased risk of hepatotoxicity

Advise against adding the medication because the absolute risk reduction is only 2% and it poses a high risk of drug-drug interactions with his current lipid-lowering therapy

Advise against adding the medication because its concomitant use with his current antihyperglycemic agent causes an unacceptable synergistic risk of hepatic failure

Show answer & explanation

Answer: Advise against adding the medication because the absolute risk reduction is only 2% and it poses a high risk of drug-drug interactions with his current lipid-lowering therapy

Answer

Advise against adding the medication because the absolute risk reduction is only 2% and it poses a high risk of drug-drug interactions with his current lipid-lowering therapy.

The correct answer identifies that the actual absolute risk reduction (ARR) is only

2.0\%

(

6.0\% - 4.0\%

), not the

33\%

relative risk reduction touted in the advertisement. Furthermore, the patient is currently taking atorvastatin for hyperlipidemia. Atorvastatin is extensively metabolized by the hepatic cytochrome P450 3A4 (CYP3A4) isoenzyme. The literature summary states the new drug is a strong CYP3A4 inhibitor. Combining a strong CYP3A4 inhibitor with atorvastatin significantly increases serum statin concentrations, creating an unacceptably high risk for statin-induced myopathy and life-threatening rhabdomyolysis. Therefore, despite a modest statistical benefit, the severe pharmacokinetic interaction makes this medication inappropriate for this patient.

Step-by-Step Solution

Identify the absolute risk reduction (ARR) from the provided literature.

ARR = 6.0\% - 4.0\% = 2.0\%

Drug advertisements often highlight Relative Risk Reduction (33%) to inflate perceived efficacy, making it essential to calculate ARR for clinical decision making.

Calculate the Number Needed to Treat (NNT).

NNT = \frac{1}{ARR} = \frac{1}{0.02} = 50

NNT provides practical clinical context on how many patients must be treated to prevent one outcome over the study period.

Evaluate the patient's current medication list for potential drug-drug interactions with the new agent.

The patient is taking atorvastatin. The new drug is a strong CYP3A4 inhibitor.

Atorvastatin is heavily metabolized by CYP3A4; concurrent use with strong inhibitors can cause life-threatening rhabdomyolysis.

Synthesize the risk-benefit ratio to make a clinical recommendation.

The benefit (preventing 1 MACE per 50 patients) is outweighed by the severe risk of statin toxicity.

Absolute contraindications or severe interaction risks preclude the use of drugs with marginal absolute benefits.

Key Concept

Critical appraisal of drug advertisements requires distinguishing absolute from relative risk reduction and applying trial safety data to individual patient pharmacotherapy to prevent adverse drug events.

Question 3622Question →

A pediatric researcher is analyzing the birth weights of full-term neonates born at 39 weeks of gestation at a large regional hospital. The dataset, which includes 5,000 infants, follows a normal distribution. The analysis reveals a mean birth weight of $3,400$ g and a variance of $90,000 \text{ g}^2$ . For a secondary analysis, the researcher needs to identify the birth weight threshold for the lowest $2.5\%$ of the cohort. Based on the empirical rule, what is the maximum birth weight (in grams) that would fall into the lowest $2.5\%$ of this distribution?

Show answer & explanation

Answer: 2800

Answer

2800

The correct threshold is

2,800

g. In a normal distribution, the empirical (68-95-99.7) rule states that approximately

95\%

of the data falls within two standard deviations (

2

SD) of the mean. This leaves

5\%

of the data in the tails, evenly distributed as

2.5\%

in the lower tail and

2.5\%

in the upper tail. Therefore, the lowest

2.5\%

of neonates corresponds to birth weights that are exactly

2

SD below the mean. The standard deviation is the square root of the variance, so

\sqrt{90,000} = 300

g. Subtracting

2

SD from the mean of

3,400

g yields

3,400 - 2(300) = 2,800

Step-by-Step Solution

Calculate the standard deviation from the given variance.

\sqrt{90,000} = 300

The empirical rule and normal distribution properties are based on standard deviation, not variance.

Determine the number of standard deviations from the mean corresponding to the 2.5th percentile.

2

standard deviations below the mean.

According to the empirical rule (68-95-99.7),

95\%

of values lie within

2

standard deviations of the mean. Due to the symmetry of the normal distribution, the remaining

5\%

is split equally between the two tails, meaning

2.5\%

of values fall below

-2

standard deviations.

Calculate the specific birth weight threshold.

3,400 - (2 \times 300) = 2,800

Subtracting

2

standard deviations from the mean provides the maximum birth weight that falls into the lowest

2.5\%

of the distribution.

Key Concept

Applying the empirical rule (68-95-99.7) to a normal distribution and deriving standard deviation from variance.

Question 3623Question →

A physician is reviewing promotional materials and abstracts for several newly approved medications. To accurately evaluate these clinical claims, the physician must understand fundamental biostatistical terminology. Match the following biostatistical terms to their corresponding clinical trial excerpts or definitions commonly found in drug advertisements.

Click a left item, then click its matching right item

Show answer & explanation

Answer

ARR matches the raw percentage point decrease; NNT matches the number of patients treated to prevent one event; RRR matches the proportional decrease relative to the control; Surrogate Endpoint matches the use of a biomarker (HbA1c) instead of a clinical complication.

Accurate interpretation of drug advertisements requires distinguishing between different measures of effect. Absolute Risk Reduction (ARR) shows the actual difference in event rates. Number Needed to Treat (NNT), derived from ARR, provides a practical clinical metric of effort to benefit. Relative Risk Reduction (RRR) shows proportional change and can inflate perceived benefit. Surrogate endpoints are laboratory or physiologic measures used as substitutes for direct clinical outcomes.

Step-by-Step Solution

Analyze the excerpt describing a 4 percentage point decrease.

Identify this as a simple subtraction of event rates.

This defines Absolute Risk Reduction (ARR).

Evaluate the statement about treating 25 patients to prevent one event.

Identify this as a ratio indicating the clinical effort required for a specific benefit.

This is the classic definition of Number Needed to Treat (NNT).

Assess the 30% lower risk relative to the control group.

Recognize this as a proportional change rather than an absolute rate change.

This describes Relative Risk Reduction (RRR).

Review the focus on HbA1c instead of clinical complications.

Identify HbA1c as a laboratory marker substituting for actual clinical disease outcomes.

This is the definition of a Surrogate Endpoint.

Key Concept

Understanding and identifying fundamental biostatistical terms (ARR, RRR, NNT, surrogate endpoints) used in medical literature and drug advertisements.

Question 3624Question →

A large epidemiological study is investigating a novel serum biomarker, alpha-7-glycoprotein (A7G), to predict incident heart failure in adults over age $50$ . The A7G levels in the study population ( $N = 10,000$ ) are determined to follow a normal distribution. Preliminary statistical analysis reveals that $16\%$ of the participants have an A7G level greater than $45 \text{ mg/L}$ , while $2.5\%$ of the participants have an A7G level less than $21 \text{ mg/L}$ .

Based on these findings, what is the variance of the A7G levels in this study population? (Provide your answer as a numeric value)

Show answer & explanation

Answer: 64

Answer

The problem requires applying the 68-95-99.7 (empirical) rule for normally distributed data. According to this rule, approximately

68\%

of values lie within

1

standard deviation (SD) of the mean, leaving

32\%

outside this range (

16\%

in each tail). Therefore, the value

45 \text{ mg/L}

, above which

16\%

of the data falls, represents the mean plus

1\text{ SD}

(

\mu + 1\sigma = 45

). Similarly,

95\%

of values lie within

2\text{ SDs}

of the mean, leaving

5\%

outside (

2.5\%

in each tail). The value

21 \text{ mg/L}

, below which

2.5\%

of the data falls, represents the mean minus

2\text{ SDs}

(

\mu - 2\sigma = 21

). Subtracting the second equation from the first yields

3\sigma = 24

, so

\sigma = 8 \text{ mg/L}

. The question asks for the variance, which is the square of the standard deviation (

\sigma^2 = 8^2 = 64

). Thus, the variance is

64

Step-by-Step Solution

Identify the percentiles given in the clinical vignette and relate them to the empirical rule (68-95-99.7 rule) for a normal distribution.

16% above 45 mg/L corresponds to the top tail outside 1 standard deviation (SD). 2.5% below 21 mg/L corresponds to the bottom tail outside 2 SDs.

In a normal distribution, 68% of data falls within 1 SD of the mean (leaving 32% outside, or 16% in each tail). 95% of data falls within 2 SDs (leaving 5% outside, or 2.5% in each tail).

Translate the percentiles into a system of algebraic equations using the mean (\mu) and standard deviation (\sigma).

Equation 1: \mu + 1\sigma = 45. Equation 2: \mu - 2\sigma = 21.

This establishes the mathematical relationship between the known values and the unknown distribution parameters.

Solve the system of linear equations to find the standard deviation (\sigma).

Subtracting Equation 2 from Equation 1 yields: (\mu + 1\sigma) - (\mu - 2\sigma) = 45 - 21. Therefore, 3\sigma = 24, which means \sigma = 8 mg/L.

Isolating \sigma allows us to determine the standard deviation, which is required to find the variance.

Calculate the variance by squaring the standard deviation.

Variance = \sigma^2 = 8^2 = 64.

Variance is defined mathematically as the square of the standard deviation.

Key Concept

Applying the empirical rule (68-95-99.7) to a normal distribution to determine standard deviation and variance.

Question 3625Question →

A clinical pharmacologist is analyzing the steady-state trough concentrations of a newly approved monoclonal antibody targeted for severe refractory eosinophilic asthma. In a post-marketing surveillance cohort of $5,000$ adult patients, the serum trough concentrations follow a normal, symmetric bell-shaped distribution.

The variance of the steady-state trough concentrations in this population is calculated to be $9.0 \text{ (mcg/mL)}^2$ . Furthermore, statistical analysis reveals that the $84^\text{th}$ percentile for the trough concentration is $17.0 \text{ mcg/mL}$ .

The clinical trial protocol dictates that any patient with a trough concentration falling at or below the $2.5^\text{th}$ percentile is at extremely high risk for subtherapeutic exposure and should undergo immediate dose escalation.

Below what trough concentration (in $\text{mcg/mL}$ ) will a patient qualify for this dose escalation?

Show answer & explanation

Answer: 8

Answer

The threshold for the dose escalation is 8.0 mcg/mL.

In a perfectly normal distribution, percentiles directly map to standard deviations away from the mean based on the 68-95-99.7 rule. The standard deviation is the square root of the variance (

9.0

), which is

3.0

. Because

68\%

of values lie within

1

standard deviation, the upper boundary of this central area (

50\% + 34\% = 84\%

) represents the

84^\text{th}

percentile. This means

\mu + 1\sigma = 17.0

. Given

\sigma = 3.0

, the mean

\mu = 14.0

. The protocol requires finding the

2.5^\text{th}

percentile. Because

95\%

of values lie within

2

standard deviations,

5\%

lie outside this range, leaving

2.5\%

symmetrically in the lower tail. Therefore, the

2.5^\text{th}

percentile is

\mu - 2\sigma

, which evaluates to

14.0 - 2(3.0) = 8.0 \text{ mcg/mL}

Step-by-Step Solution

Calculate the standard deviation (

\sigma

) by taking the square root of the population variance.

\sigma = \sqrt{9.0} = 3.0 \text{ mcg/mL}

The empirical rule (68-95-99.7) requires the use of standard deviation, not variance.

Map the

84^\text{th}

percentile to its position on the normal distribution using the empirical rule.

The

84^\text{th}

percentile corresponds to

+1\sigma

above the mean.

In a normal distribution,

50\%

of the data lies below the mean. The first standard deviation above the mean contains

34\%

of the data. Thus,

50\% + 34\% = 84\%

, meaning the

84^\text{th}

percentile is exactly at

\mu + 1\sigma

Calculate the population mean (

\mu

) using the value of the

84^\text{th}

percentile and the standard deviation.

\mu + 1(3.0) = 17.0 \implies \mu = 14.0 \text{ mcg/mL}

Establishing the mean is required to find any other specific percentile value in the distribution.

Map the

2.5^\text{th}

percentile to its position on the normal distribution.

The

2.5^\text{th}

percentile corresponds to

-2\sigma

below the mean.

According to the empirical rule,

95\%

of data falls within

\pm 2\sigma

. This leaves

5\%

in the combined tails, meaning exactly

2.5\%

lies in the lower tail (below

-2\sigma

Calculate the exact trough concentration for the

2.5^\text{th}

percentile threshold.

14.0 - 2(3.0) = 14.0 - 6.0 = 8.0 \text{ mcg/mL}

This is the final application of the derived mean and standard deviation to identify the specific clinical threshold requested.

Key Concept

Application of the empirical (68-95-99.7) rule to a normal distribution, including the conversion of variance to standard deviation to calculate specific clinical percentiles.

Estimated Time:3m 0s

Question 3626Question →

Match the following clinical trial methodologies or drug advertisement strategies with their corresponding epidemiological implications or potential biases.

Click a left item, then click its matching right item

Show answer & explanation

Answer

Modified ITT pairs with selection bias risk; Composite endpoints pair with misleading impact on severe outcomes; Active run-in phases pair with compromised external validity; Relative metrics pair with magnified perceived benefit.

Each methodological strategy corresponds directly to a specific epidemiological consequence. Accurately matching these concepts demonstrates the ability to critically evaluate the validity, safety, and clinical applicability of clinical trial data and promotional materials.

Step-by-Step Solution

Analyze the Modified Intention-to-Treat (mITT) statement.

Matched with the disruption of baseline prognostic balance.

True ITT includes all randomized patients. Excluding those who didn't receive a dose violates this principle, potentially introducing selection bias and compromising internal validity.

Analyze the composite endpoint statement.

Matched with the use of less critical events to power the study.

Composite endpoints often achieve significance through frequent, less severe events, while crucial outcomes like mortality may remain unaffected.

Analyze the active-drug run-in phase statement.

Matched with compromised external validity.

Filtering out intolerant patients before randomization makes the final study population less representative of the general clinical population, artificially lowering expected adverse event rates.

Analyze the 50% risk reduction statement.

Matched with magnifying perceived clinical benefit.

A drop from 0.2% to 0.1% is a 50% Relative Risk Reduction but only a 0.1% Absolute Risk Reduction. Drug ads often emphasize RRR to make effects appear larger.

Key Concept

Critical appraisal of medical literature requires recognizing how study design choices (like mITT, run-in phases, composite endpoints) and data presentation (RRR vs. ARR) can bias results or mislead clinical interpretation.

Estimated Time:2m 0s

Question 3627Question →

During a morning report session, an internal medicine resident evaluates a manufacturer-sponsored slide deck for a newly approved migraine prophylactic medication. The featured slide contains a bar graph summarizing the primary outcome: the proportion of patients completely free of migraines at $6$ months. The data indicate that $12\%$ of the patients taking the new medication achieved migraine freedom, whereas $8\%$ of the placebo group achieved the same endpoint. The slide prominently highlights a " $50\%$ relative increase in migraine freedom" for the treatment group. Based on these results, how many patients need to receive the new medication instead of the placebo to result in one additional patient achieving migraine freedom at $6$ months?

2

8

12

25

50

Show answer & explanation

Answer: $25$

Answer

The Number Needed to Treat (NNT) is

25

To find the number of patients that must be treated to achieve one additional positive outcome, the Number Needed to Treat (NNT) must be calculated. The first step is to calculate the Absolute Risk Reduction (ARR), which is the absolute difference in outcome rates between the experimental and control groups. Here, the treatment rate is

12\%

and the placebo rate is

8\%

. Thus,

\text{ARR} = 12\% - 8\% = 4\%

, or

0.04

. The NNT is the inverse of the ARR:

\frac{1}{0.04} = 25

. Therefore,

25

patients must be treated with the new medication instead of a placebo to achieve one additional instance of migraine freedom.

Step-by-Step Solution

Calculate the Absolute Risk Reduction (ARR) by finding the difference in event rates between the treatment and placebo groups.

12\% - 8\% = 4\%

(or

0.04

)

ARR is required to calculate the absolute clinical impact of the intervention, filtering out the potentially misleading relative risk differences.

Calculate the Number Needed to Treat (NNT) by taking the inverse of the ARR.

\text{NNT} = \frac{1}{0.04} = 25

NNT tells us the average number of patients who need to be treated to prevent one additional bad outcome (or achieve one additional positive outcome).

Key Concept

Calculating Number Needed to Treat (NNT) from absolute risk differences in medical literature

Question 3628Question →

A physician is critically appraising a newly published randomized controlled trial evaluating a novel biologic agent for rheumatoid arthritis. The study's findings are heavily featured in a recent drug advertisement. Match each excerpted methodological description from the trial or advertisement to the specific critical appraisal concept or bias it most accurately represents.

Click a left item, then click its matching right item

Show answer & explanation

Answer

The descriptions correctly match with reliance on surrogate endpoints, attrition bias, per-protocol analysis, and threat to external validity, respectively.

Each methodological flaw accurately corresponds to its specific critical appraisal concept. Recognizing these issues is essential for determining the true validity and clinical applicability of pharmaceutical claims.

Step-by-Step Solution

Analyze the first description regarding the reduction in C-reactive protein without clinical data.

This describes the promotion of a laboratory value rather than a meaningful patient outcome, identifying it as reliance on a surrogate endpoint.

Surrogate endpoints are often used in drug advertisements to imply efficacy, but they must be distinguished from true clinical endpoints.

Evaluate the second description concerning the exclusion of patients who withdrew due to side effects.

This selective loss of participants from the analysis introduces a systematic error, specifically attrition bias.

When dropouts are related to the intervention and are excluded, the remaining groups are no longer comparable, violating the intention-to-treat principle.

Assess the third description about analyzing only fully compliant participants.

This methodology ignores original randomization and only looks at compliers, which is the definition of a per-protocol analysis.

Per-protocol analyses often overestimate treatment effects compared to intention-to-treat analyses.

Review the fourth description regarding the mismatch between the study population and the advertised target population.

This discrepancy means the study results may not apply to the advertised demographic, representing a threat to external validity.

External validity refers to the ability to generalize study findings to other populations or settings.

Key Concept

Critical appraisal of medical literature requires identifying methodological flaws and biases, such as inappropriate use of surrogate endpoints, attrition bias, per-protocol analysis, and poor external validity, to accurately evaluate the clinical utility of drug advertisements.

Question 3629Question →

An internal medicine physician is critically reviewing a recently published multicenter cohort study evaluating a novel serum biomarker, interleukin-6 (IL-6) receptor level, as a predictor of $30$ -day mortality in patients with septic shock. The study enrolled $2,500$ patients across various intensive care units. In the baseline characteristics table, the authors describe the distribution of the initial IL-6 receptor levels (measured in $pg/mL$ ). They note that the data are highly asymmetrical: the vast majority of patients have very low circulating levels of the biomarker, but a small, distinct subset of patients presents with exceedingly high levels. Based on the characteristics of this continuous variable, which of the following statements regarding its distribution and appropriate descriptive statistics is most accurate?

The distribution is positively skewed with the mean greater than the median, and the median and interquartile range are the most appropriate summary measures.

The distribution is positively skewed with the mean greater than the median, and the mean and standard deviation are the most appropriate summary measures.

The distribution is negatively skewed with the mean less than the median, and the median and interquartile range are the most appropriate summary measures.

The distribution is negatively skewed with the mean less than the median, and the mean and standard deviation are the most appropriate summary measures.

The serum biomarker represents an ordinal data type, and frequencies and proportions are the most appropriate summary measures.

Show answer & explanation

Answer: The distribution is positively skewed with the mean greater than the median, and the median and interquartile range are the most appropriate summary measures.

Answer

The distribution is positively skewed with the mean greater than the median, and the median and interquartile range are the most appropriate summary measures.

The correct answer accurately identifies the distribution as positively (right) skewed. In this scenario, the statement that the 'vast majority of patients have very low... levels' and a 'small, distinct subset... presents with exceedingly high levels' clearly describes a long tail to the right. Because the mean is heavily influenced by extreme values, these exceptionally high biomarker levels pull the mean to the right, making the mean greater than the median. When continuous data are asymmetrical, traditional parametric measures (mean and standard deviation) become distorted and misleading. Therefore, robust non-parametric measures—specifically, the median for central tendency and the interquartile range (IQR) for dispersion—are the most appropriate statistical summaries.

Step-by-Step Solution

Analyze the description of the data distribution provided in the stem.

The vast majority of values are low, with a small number of extremely high values.

This indicates the direction of the tail. A long tail extending toward the higher values means the data is skewed to the right (positively skewed).

Determine the relationship between the measures of central tendency for this distribution.

In a right-skewed distribution, the mean is pulled strongly in the direction of the long tail of extreme values.

Because the extreme high values inflate the arithmetic average, the mean becomes greater than the median (and the mode).

Select the most appropriate descriptive statistics for this type of data.

The median and interquartile range (IQR) should be used.

Parametric measures like the mean and standard deviation are easily distorted by outliers and skewed distributions. Non-parametric measures (median, IQR) are robust and provide a more accurate representation of the central tendency and dispersion.

Key Concept

In positively (right) skewed distributions, extreme high values pull the mean toward the long tail, resulting in the mean being greater than the median. Skewed continuous variables should be summarized using the median and interquartile range (IQR) because these measures are resistant to outliers.

Question 3630Question →

A clinical pathology committee is establishing a reference interval for a newly implemented assay measuring baseline serum total immunoglobulin E (IgE) levels. Data are collected from a cohort of $3,000$ healthy adult volunteers with no history of atopy. The distribution of the resulting data shows a mode of $15 \text{ IU/mL}$ and a median of $42 \text{ IU/mL}$ . The data exhibits a long tail extending to the right, with rare values exceeding $300 \text{ IU/mL}$ . To define the central $95\%$ reference interval representing the normal population, the laboratory director proposes calculating the arithmetic mean and setting the boundaries at the mean $\pm 2$ standard deviations. Which of the following describes the most significant statistical flaw in this proposed methodology?

Applying the empirical rule to a positively skewed distribution will yield an inaccurate estimate of the true population percentiles.

The interquartile range should be used in place of standard deviation because it precisely captures the central 95% of skewed data.

The data distribution is negatively skewed, which requires a logarithmic transformation before calculating the arithmetic mean.

The laboratory values represent ordinal data, making the mathematical calculation of a mean and standard deviation invalid.

A non-parametric inferential statistical test must be performed before descriptive limits can be established.

Show answer & explanation

Answer: Applying the empirical rule to a positively skewed distribution will yield an inaccurate estimate of the true population percentiles.

Answer

Applying the empirical rule to a positively skewed distribution will yield an inaccurate estimate of the true population percentiles.

The empirical rule (which states that approximately

68\%

95\%

, and

99.7\%

of data fall within

1

2

, and

3

standard deviations of the mean, respectively) strictly applies only to normally distributed (Gaussian) data. In this scenario, the mode (

15 \text{ IU/mL}

) is significantly less than the median (

42 \text{ IU/mL}

), and there is a long tail of high values extending to

300 \text{ IU/mL}

. These characteristics define a positively (right) skewed distribution. When data are highly skewed, the arithmetic mean is pulled toward the long tail, becoming larger than the median. Applying the mean

\pm 2

standard deviations to such data will inaccurately estimate the true boundaries of the central

95\%

of the population. In many biomedical contexts with positive skew, this flawed method results in a calculated lower limit that is a negative number, which is impossible for a concentration. Instead, non-parametric methods, such as directly calculating the

2.5\text{th}

and

97.5\text{th}

percentiles, should be utilized to establish the reference interval.

Step-by-Step Solution

Determine the data type and the shape of the distribution.

Serum IgE is a continuous variable. Because the mode (

15 \text{ IU/mL}

) is lower than the median (

42 \text{ IU/mL}

) and there is a long tail to the right, the distribution is positively (right) skewed.

Identifying the distribution shape is required to select appropriate statistical summary measures.

Evaluate the laboratory director's proposed statistical method.

The director proposes using the mean

\pm 2

standard deviations to capture

95\%

of the data. This relies on the 68-95-99.7 (empirical) rule.

We must identify the underlying statistical assumption being applied.

Assess the validity of the empirical rule for this specific dataset.

The empirical rule is only valid for normally distributed (Gaussian) data. Applying it to highly positively skewed data will result in a distorted interval, often yielding a clinically impossible negative lower bound and failing to accurately represent the true

2.5\text{th}

and

97.5\text{th}

percentiles.

Matching the statistical rule to its strict distribution requirement reveals the methodological flaw.

Key Concept

Data Types, Distributions, and Descriptive Statistics

Question 3631Question →

A medical resident is presenting a recent multicenter, randomized controlled trial at journal club. The trial evaluated a novel medication, neprastatin, for the prevention of acute exacerbations in patients with severe chronic obstructive pulmonary disease (COPD). The study enrolled 5,000 patients, with 2,500 randomly assigned to receive daily neprastatin and 2,500 assigned to receive a placebo. At the end of the 2-year follow-up period, the published abstract states that 150 patients in the placebo group experienced an acute COPD exacerbation, compared to 100 patients in the neprastatin group.

Based on the results presented in the abstract, what is the number needed to treat (NNT) with neprastatin to prevent one acute COPD exacerbation?

Show answer & explanation

Answer: 50

Answer

To calculate the Number Needed to Treat (NNT), one must first find the Absolute Risk Reduction (ARR). The Control Event Rate (CER) is the risk of the event in the placebo group:

150 / 2500 = 0.06

(or

6\%

). The Experimental Event Rate (EER) is the risk of the event in the intervention group:

100 / 2500 = 0.04

(or

4\%

). The ARR is the difference between these two rates:

CER - EER = 0.06 - 0.04 = 0.02

. The NNT is the inverse of the ARR (

1 / ARR

), which evaluates to

1 / 0.02 = 50

. This means 50 patients must be treated with neprastatin to prevent one acute COPD exacerbation.

Step-by-Step Solution

Identify the number of events and total patients in each group from the abstract.

Placebo group: 150 events out of 2,500 patients. Neprastatin group: 100 events out of 2,500 patients.

These values are required to calculate the event rates for both the control and experimental groups.

Calculate the Control Event Rate (CER).

CER = \frac{150}{2500} = 0.06

CER represents the baseline risk of the event occurring without the new intervention.

Calculate the Experimental Event Rate (EER).

EER = \frac{100}{2500} = 0.04

EER represents the risk of the event occurring with the new intervention.

Calculate the Absolute Risk Reduction (ARR).

ARR = CER - EER = 0.06 - 0.04 = 0.02

ARR measures the absolute difference in risk between the two groups.

Calculate the Number Needed to Treat (NNT).

NNT = \frac{1}{ARR} = \frac{1}{0.02} = 50

NNT is defined as the inverse of the ARR.

Key Concept

Number Needed to Treat (NNT) calculation from clinical trial data

Estimated Time:1m 0s

Question 3632Question →

A public health task force is designing a comprehensive registry to track outcomes of patients with chronic cardiovascular conditions. The database architect requires the medical team to classify each collected variable into its fundamental statistical data type to ensure appropriate downstream statistical analysis. Match each clinical variable collected in the registry to its correct statistical data type.

Click a left item, then click its matching right item

Show answer & explanation

Answer

Serum BNP concentration is a continuous variable. NYHA functional classification is an ordinal variable. Total number of emergency department visits is a discrete variable. Patient primary language is a nominal variable.

Proper classification of variables dictates the appropriate descriptive statistics and inferential statistical tests that can be performed. Continuous variables can take any value, discrete variables are countable integers, ordinal variables have a logical rank but unequal intervals, and nominal variables are purely named categories without order.

Step-by-Step Solution

Analyze the serum BNP concentration.

Determined to be a continuous variable.

Laboratory values like concentration can take any numerical value within a range, including fractions and decimals.

Evaluate the NYHA functional classification.

Determined to be an ordinal variable.

The classes have an inherent ranking (I to IV indicating worsening severity) but the magnitude of difference between classes is not uniform or measurable.

Assess the total number of emergency department visits.

Determined to be a discrete variable.

Visits are counted in whole integers; fractional visits are impossible.

Review the patient primary language.

Determined to be a nominal variable.

Languages are named categories without any mathematical ranking or inherent order.

Key Concept

Data types in biostatistics are fundamentally divided into numerical (continuous, discrete) and categorical (ordinal, nominal) classifications.

Question 3633Question →

A peer-review panel is evaluating the statistical methods sections of four distinct clinical research manuscripts submitted for publication. Match each manuscript's data description with the most accurate statistical principle regarding its distribution or appropriate descriptive measure.

Click a left item, then click its matching right item

Show answer & explanation

Answer

Manuscript 1 pairs with negative skewness. Manuscript 2 pairs with a normal distribution and an implied standard deviation of 8 mg/dL. Manuscript 3 pairs with positive skewness. Manuscript 4 pairs with ordinal data requiring non-parametric measures.

The correct pairs are established by analyzing central tendency and data types. Manuscript 1 describes a scenario where the mean (45 days) is significantly lower than the median (62 days). This indicates a negatively skewed (left-skewed) distribution, where a tail of smaller values pulls the mean down while leaving the median relatively stable. Manuscript 2 describes a symmetric normal distribution (mean equals median) where approximately 68% of the data falls within a specific range. According to the 68-95-99.7 empirical rule, 68% of values fall within one standard deviation of the mean. Since the range is 92 ± 8 mg/dL, the standard deviation is 8 mg/dL. Manuscript 3 describes a scenario where the mean (15.4 pg/mL) is significantly higher than the median (8.2 pg/mL). This indicates a positively skewed (right-skewed) distribution, where a tail of large, extreme values pulls the mean upward. Manuscript 4 involves a Likert-type pain scale, which is ordinal data. While often incorrectly analyzed using means in literature, the intervals between values are not objectively equal, making medians and interquartile ranges (IQR) the most rigorous summary measures.

Step-by-Step Solution

Analyze Manuscript 1's summary statistics.

Mean (45) is less than the Median (62).

Comparing the mean and median is the primary initial step to determine the direction of distribution skewness.

Analyze Manuscript 2's summary statistics.

Mean equals Median (92); 68% of values fall between 84 and 100 mg/dL.

Identifying a symmetric normal distribution allows application of the empirical (68-95-99.7) rule to calculate the standard deviation.

Analyze Manuscript 3's summary statistics.

Mean (15.4) is greater than the Median (8.2).

When the mean is pulled to the right of the median, it indicates positive skewness caused by extreme high outliers.

Determine the data type for Manuscript 4.

A Likert pain scale represents ordinal qualitative data.

Identifying the correct data type dictates the appropriate descriptive statistics (median/IQR rather than mean/SD).

Key Concept

The relationship between mean and median determines distribution skewness, the empirical rule allows estimation of standard deviation in normal distributions, and ordinal data should theoretically be summarized with non-parametric statistics.

Question 3634Question →

A 72-year-old man presents to the clinic to discuss adding a newly approved medication, myotropib, for his heart failure with preserved ejection fraction (HFpEF). He currently takes a loop diuretic, an angiotensin II receptor blocker, and a beta-blocker. His medical history is also notable for severe chronic obstructive pulmonary disease (COPD) requiring continuous home oxygen therapy.

The physician reviews a promotional brochure provided by the manufacturer. The brochure highlights the primary results of a large, randomized, double-blind, placebo-controlled trial, demonstrating that myotropib reduces the composite endpoint of heart failure hospitalization and cardiovascular death by a relative risk of 30% (Hazard Ratio [HR] 0.70, 95% Confidence Interval [CI] 0.62–0.79, $p < 0.001$ ).

The physician then examines the supplementary appendix of the trial, which includes the following subgroup analysis data for the primary endpoint:

Subgroup	Number of Patients	HR (95% CI)
Overall Cohort	8,400	0.70 (0.62–0.79)
Age	$0.45$
$< 65$ years	3,200	0.68 (0.55–0.84)
$\geq 65$ years	5,200	0.71 (0.61–0.83)
COPD Status	$0.002$
No COPD	6,100	0.55 (0.48–0.63)
COPD	2,300	0.99 (0.85–1.15)

Based on the provided literature excerpt and the patient's history, which of the following is the most accurate interpretation of the data and the most appropriate clinical decision?

COPD status acts as an effect modifier; do not initiate the medication as the patient is unlikely to derive cardiovascular benefit.

COPD status is a confounding variable; initiate the medication because randomization adequately controls for baseline differences.

The interaction analysis utilized an inappropriate statistical test for time-to-event data; initiate the medication based on the overall trial efficacy.

The hazard ratio for patients with COPD indicates a toxic pharmacodynamic interaction; do not initiate the medication as it is absolutely contraindicated.

The trial data requires isolated laboratory confirmation of baseline inflammatory markers before application; order a C-reactive protein level before deciding.

Show answer & explanation

Answer: COPD status acts as an effect modifier; do not initiate the medication as the patient is unlikely to derive cardiovascular benefit.

Answer

COPD status acts as an effect modifier; do not initiate the medication as the patient is unlikely to derive cardiovascular benefit.

The correct answer accurately identifies that COPD status is an effect modifier. This is evidenced by the differing hazard ratios between the strata (0.55 vs. 0.99) and the statistically significant interaction term (

p = 0.002

). Because the patient has COPD, the physician must look at the specific HR for that subgroup (0.99, 95% CI 0.85-1.15). Since the confidence interval crosses 1.0, the drug provides no statistically significant cardiovascular benefit for patients with COPD, making it inappropriate to initiate.

Step-by-Step Solution

Analyze the subgroup data for Age and COPD status, focusing on the hazard ratios (HR), confidence intervals (CI), and interaction p-values.

The Age subgroup shows no significant interaction (

p = 0.45

) and similar HRs across strata. The COPD subgroup shows a highly significant interaction (

p = 0.002

) with markedly different HRs between those with COPD (HR 0.99) and without COPD (HR 0.55).

Interaction p-values determine if a third variable significantly alters the treatment effect across different strata.

Identify the statistical phenomenon occurring in the COPD subgroup.

The differing magnitude of effect between strata combined with a statistically significant interaction term defines effect modification.

Effect modification occurs when the true effect of an exposure on an outcome varies depending on the level of a third variable. It is a biological phenomenon to be reported, unlike confounding, which is a distortion to be controlled.

Apply the subgroup findings to the specific patient in the vignette.

The patient has severe COPD. In the trial, patients with COPD had an HR of 0.99 with a 95% CI of 0.85–1.15.

To practice evidence-based medicine, trial data must be applied directly to the patient's characteristics when valid subgroup data exists.

Interpret the clinical meaning of the HR for the patient's subgroup and formulate a management plan.

Because the 95% CI for the COPD subgroup crosses 1.0, there is no statistically significant difference in outcomes between the drug and placebo. The medication should not be prescribed as it offers no benefit.

A hazard ratio whose confidence interval includes 1.0 indicates a lack of statistical significance, meaning the null hypothesis (no difference between groups) cannot be rejected.

Key Concept

Effect modification is present when the effect of an exposure on an outcome differs across strata of a third variable, indicated by a significant interaction p-value. In clinical literature, this guides personalized medical decisions based on patient characteristics.

Question 3635Question →

A hospital administration team is analyzing the length of stay for all patients admitted with acute heart failure exacerbations over the past $12$ months. The analysis reveals that the vast majority of patients respond well to initial diuresis and are discharged within $3$ to $5$ days. However, a small proportion of patients develop cardiogenic shock requiring prolonged intensive care, mechanical support, and complex medication regimens, resulting in hospitalizations lasting $30$ to $60$ days. The data is compiled into a continuous distribution curve. Which of the following statements is most accurate regarding the descriptive statistics for this dataset?

The mean is greater than the median, and the interquartile range is the preferred measure of dispersion.

The mean is greater than the median, and the standard deviation is the preferred measure of dispersion.

The mean is less than the median, and the interquartile range is the preferred measure of dispersion.

The mean is less than the median, and the standard deviation is the preferred measure of dispersion.

The mean and median are approximately equal, and the standard deviation is the preferred measure of dispersion.

Show answer & explanation

Answer: The mean is greater than the median, and the interquartile range is the preferred measure of dispersion.

Answer

The mean is greater than the median, and the interquartile range is the preferred measure of dispersion.

The clinical scenario describes a classic positively skewed (right-skewed) distribution. Most of the data is clustered at the lower end (shorter hospital stays of

3

5

days), while a long 'tail' extends to the right due to a few extreme outliers (prolonged stays of

30

60

days). In such distributions, the extreme high values pull the mean to the right, causing the mean to be greater than the median. Because the mean and standard deviation are highly sensitive to these extreme values, they do not accurately reflect the typical patient's experience. Instead, robust non-parametric measures—specifically the median for central tendency and the interquartile range (IQR) for dispersion—should be used to summarize skewed data.

Step-by-Step Solution

Determine the shape of the data distribution based on the clinical vignette.

The dataset has a large cluster of low values (

3

5

days) and a long tail of high extreme values (

30

60

days), indicating a positively skewed (right-skewed) distribution.

Identifying the distribution shape is required to understand how measures of central tendency relate to each other.

Determine the relationship between the mean and median for this specific distribution.

In a positively skewed distribution, the extreme high values disproportionately pull the mean toward the right tail, making the mean greater than the median.

The mean is highly sensitive to outliers, whereas the median is a robust measure that remains anchored near the center of the data cluster.

Select the appropriate measure of dispersion for the identified distribution.

The interquartile range (IQR) is the preferred measure of dispersion.

Standard deviation and variance are derived using the mean and assume a normal distribution; they misrepresent the spread of skewed data. Non-parametric measures like the IQR (and median for central tendency) are the standard statistical choices for highly skewed data.

Key Concept

In a positively skewed distribution, the mean is greater than the median. For skewed data, non-parametric statistics (median and interquartile range) are the most appropriate measures of central tendency and dispersion.

Question 3636Question →

A $64$ -year-old man with a history of hyperlipidemia and stage $3$ chronic kidney disease (CKD) visits his primary care physician. He is currently managed with a moderate-intensity statin. The physician recently reviewed a promotional drug advertisement for a novel add-on lipid-lowering medication. The ad prominently displays a hazard ratio (HR) of $0.75$ ( $95\% \text{ CI}: 0.66 - 0.85$ ) for the reduction of major adverse cardiovascular events compared to statin therapy alone, based on a large randomized controlled trial.

To determine if this medication is appropriate for this specific patient, the physician retrieves the original peer-reviewed publication. The publication includes a forest plot detailing subgroup analyses. The stratum-specific results based on baseline CKD status are presented below:

* Overall Trial Population: $\text{HR} = 0.75$ ( $95\% \text{ CI}: 0.66 - 0.85$ )
* Patients without CKD: $\text{HR} = 0.55$ ( $95\% \text{ CI}: 0.45 - 0.68$ )
* Patients with CKD: $\text{HR} = 0.98$ ( $95\% \text{ CI}: 0.88 - 1.10$ )

Furthermore, the FDA package insert notes that this new medication is a strong inhibitor of the CYP3A4 enzyme.

Based on a critical appraisal of the provided literature and the patient's clinical profile, which of the following is the most appropriate interpretation and clinical decision?

The medication should not be initiated because the difference between the stratum-specific and overall hazard ratios indicates significant confounding by baseline renal function.

The medication should be initiated based on the overall trial efficacy, provided the patient's statin dose is adjusted to prevent CYP3A4-mediated toxicity.

The medication should not be initiated because the trial data demonstrate effect modification, indicating no significant cardiovascular benefit for patients with chronic kidney disease.

The medication should be initiated because the divergence between the subgroup hazard ratios implies an incorrect statistical test was applied during the analysis.

The medication should not be initiated because the negative predictive value of the primary endpoint is altered by the differing prevalence of cardiovascular events in the CKD population.

Show answer & explanation

Answer: The medication should not be initiated because the trial data demonstrate effect modification, indicating no significant cardiovascular benefit for patients with chronic kidney disease.

Answer

The medication should not be initiated because the trial data demonstrate effect modification, indicating no significant cardiovascular benefit for patients with chronic kidney disease.

The correct answer accurately identifies that the drug is not indicated for this patient due to effect modification. Effect modification occurs when the magnitude of an exposure's effect on an outcome differs depending on the level of a third variable (in this case, chronic kidney disease). Because the hazard ratio for patients with CKD is 0.98 and the 95% confidence interval (0.88-1.10) crosses 1.0, the drug demonstrates no statistically significant cardiovascular benefit in this specific subgroup. Therefore, despite the overall trial showing efficacy and the drug ad's claims, the medication should not be initiated in this patient.

Step-by-Step Solution

Analyze the overall trial results and the promotional claim.

The overall hazard ratio is 0.75, which suggests that the drug is effective in reducing cardiovascular events for the general trial population.

To understand the baseline efficacy claimed by the drug advertisement.

Evaluate the patient's specific clinical profile.

The patient is a 64-year-old man with stage 3 chronic kidney disease (CKD).

To determine which specific subgroup data from the trial applies to the patient.

Interpret the subgroup analysis for the relevant patient population.

For patients with CKD, the hazard ratio is 0.98 with a 95% confidence interval of 0.88-1.10. Because the confidence interval crosses 1.0, there is no statistically significant benefit.

To assess if the overall trial efficacy is generalizable to this specific patient.

Identify the statistical phenomenon explaining the subgroup differences.

The significant divergence between the stratum-specific hazard ratios (0.55 vs. 0.98) demonstrates effect modification by CKD status.

To correctly categorize the epidemiological concept presented in the literature and make an evidence-based clinical decision.

Key Concept

Effect modification occurs when the treatment effect differs significantly across subpopulations; evaluating these subgroup analyses is critical when applying overall trial results to individual patients.

Estimated Time:1m 30s

Question 3637Question →

A hospital therapeutics committee is evaluating a recent study on a novel biologic agent for severe uncontrolled asthma to decide on formulary inclusion. The study's baseline characteristics table summarizes the participants' prior healthcare utilization. Specifically, the number of emergency department visits per patient over the $12$ months prior to enrollment is reported with a mean of $1.5$ and a standard deviation of $2.8$ . The committee notes that the lowest possible number of emergency department visits is $0$ . Which of the following best explains why the authors' method of summarizing this specific baseline data is methodologically flawed?

The distribution is right-skewed, so the median and interquartile range should be used to describe the central tendency and dispersion.

The number of visits is an ordinal variable, meaning that calculating a mean is mathematically invalid and only the mode should be reported.

The standard deviation exceeds the mean, which indicates a left-skewed distribution where most values are clustered above the mean.

The data represents a continuous variable, which requires reporting the 95% confidence interval rather than a standard deviation for accurate interpretation.

The wide standard deviation suggests a high prevalence of effect modification, which confounds the baseline descriptive statistics.

Show answer & explanation

Answer: The distribution is right-skewed, so the median and interquartile range should be used to describe the central tendency and dispersion.

Answer

The distribution is right-skewed, so the median and interquartile range should be used to describe the central tendency and dispersion.

The correct answer accurately identifies that the data is heavily right-skewed. The variable is a count (discrete data) with a hard lower limit of

0

. A mean of

1.5

with a standard deviation of

2.8

indicates that if the distribution were symmetrical, a large proportion of patients would have a negative number of visits, which is impossible. Therefore, the data must be bunched near

0

with a long tail extending to the right (a positive, or right, skew) caused by a few outlier patients with numerous visits. Because the mean is heavily influenced by these high-end outliers, it does not represent the 'typical' patient well. In such skewed distributions, non-parametric descriptive statistics—specifically the median (for central tendency) and the interquartile range (for dispersion)—provide a much more accurate summary of the cohort.

Step-by-Step Solution

Identify the data type and its boundaries.

The 'number of emergency department visits' is a discrete quantitative variable (count data) that has an absolute minimum boundary of

0

Understanding the limits of the data is required to conceptualize its distribution shape.

Apply the properties of the mean and standard deviation to the given data.

The mean is

1.5

and the standard deviation is

2.8

. If the data were normally distributed (symmetrical), approximately

16\%

of the values would fall below one standard deviation under the mean (

1.5 - 2.8 = -1.3

Checking if a normal distribution is physically possible for the dataset reveals the underlying distribution shape.

Determine the true shape of the distribution and select the appropriate statistical measures.

Since negative visits are impossible, the data cannot be symmetrical. The large standard deviation is driven by a small number of patients with a very high number of visits, creating a long right tail (positive skew). For heavily skewed data, the median and interquartile range are the most accurate descriptors.

The mean is highly sensitive to outliers in the tail, making it artificially high and unrepresentative of the typical patient.

Key Concept

When continuous or discrete data is highly skewed (e.g., when bounded at zero with a standard deviation larger than the mean), the mean and standard deviation are misleading, and the median and interquartile range (IQR) should be used.

Question 3638Question →

A prospective cohort study investigates a novel serum biomarker (Biomarker X) for predicting disease progression in $120$ patients with idiopathic pulmonary fibrosis. Patients are categorized into three baseline severity groups: mild ( $n=40$ ), moderate ( $n=40$ ), and severe ( $n=40$ ).

The following data are collected after $1$ year of follow-up:
- Absolute change in Biomarker X levels (pg/mL) from baseline. A Shapiro-Wilk test indicates these data are severely right-skewed.
- Quality of life score on a $10$ -point Likert scale (ordinal).
- Occurrence of acute exacerbation during the $1$ -year period (dichotomous: yes/no). Across the entire cohort, a total of exactly $6$ patients experienced an exacerbation.
- The exact number of days from enrollment to the first acute exacerbation.

The researchers consult a biostatistician to finalize the data analysis plan, which will include multivariable adjustments for patient age and smoking history.

Based on the study design and data characteristics, which of the following planned statistical analyses are appropriate? (Select all that are correct)

Select all that apply

Kruskal-Wallis test to compare the absolute change in Biomarker X levels across the three baseline severity groups

Fisher's exact test to compare the occurrence of acute exacerbation across the three baseline severity groups

One-way analysis of variance (ANOVA) to compare the quality of life scores across the three baseline severity groups

Multiple logistic regression to evaluate the independent effect of baseline Biomarker X on the number of days to the first acute exacerbation, adjusting for age and smoking history

Paired Student t-test to compare the Biomarker X levels at baseline to those at

1

year within the severe group

Show answer & explanation

Answer: Kruskal-Wallis test to compare the absolute change in Biomarker X levels across the three baseline severity groups; Fisher's exact test to compare the occurrence of acute exacerbation across the three baseline severity groups

Answer

The appropriate statistical analyses are the Kruskal-Wallis test for the skewed continuous biomarker data and Fisher's exact test for the categorical exacerbation data with low expected cell counts.

The selection of statistical tests depends on the type of data (continuous, ordinal, categorical, or time-to-event), the distribution (normal vs. skewed), and the number of groups being compared. The Kruskal-Wallis test is the appropriate non-parametric alternative to one-way ANOVA for comparing a continuous, non-normally distributed variable (change in Biomarker X) across more than two independent groups (mild, moderate, severe). Fisher's exact test is the appropriate method for analyzing categorical data (occurrence of exacerbation) across independent groups when the expected frequency in any cell of the contingency table is less than 5. In this study, the overall event rate is 6 out of 120 patients. For any severity group of 40 patients, the expected number of exacerbations is exactly 2 (40 * 6/120). Since more than 20% of the cells have expected frequencies less than 5, Pearson's Chi-square test is invalid, and Fisher's exact test must be used.

Step-by-Step Solution

Analyze the variable type and distribution for the 'absolute change in Biomarker X levels'.

It is a continuous variable that is severely right-skewed, being compared across three independent groups.

Identifying the variable type, distribution, and number of groups is the first step in selecting between parametric and non-parametric tests.

Select the appropriate test for the continuous, non-normally distributed Biomarker X data.

The Kruskal-Wallis test is selected over one-way ANOVA.

Kruskal-Wallis is the non-parametric equivalent of ANOVA, required when comparing continuous data across three or more independent groups that violate the assumption of normality.

Calculate the expected cell frequencies for the 'occurrence of acute exacerbation' outcome.

It is a dichotomous variable (yes/no) across three groups (

3\times2

table). With

6

total events and

120

total patients, the expected number of events for each group of

40

(40 \times 6) / 120 = 2

The choice between Chi-square and Fisher's exact test depends on whether any expected cell frequencies in the contingency table are less than

5

Select the appropriate test for the categorical exacerbation data.

Fisher's exact test is selected over Pearson's Chi-square test.

Pearson's Chi-square is invalid because

50\%

of the cells (

3

out of

6

) have expected frequencies less than

5

. Fisher's exact test is required.

Evaluate the validity of the remaining proposed analyses based on their statistical assumptions.

ANOVA is invalid for ordinal Quality of Life data. Logistic regression is invalid for time-to-event (days to exacerbation) data. The paired t-test is invalid for paired data where the differences are highly skewed.

Applying statistical tests that violate fundamental assumptions regarding data type (e.g., treating time-to-event data as a simple binary outcome) leads to biased and invalid conclusions.

Key Concept

Selection of statistical tests based on variable scale (continuous, ordinal, categorical, time-to-event), data distribution (parametric vs. non-parametric), number of comparison groups, and sample size assumptions (expected cell frequencies).

Question 3639Question →

An epidemiologic surveillance system monitors the time to complete resolution of symptoms in a cohort of $20,000$ healthcare workers who contracted a novel upper respiratory viral infection. The symptom resolution times are normally distributed, demonstrating a mean of $18$ days and a variance of $4$ days $^2$ .

Based on the empirical (68-95-99.7) rule, what is the expected number of healthcare workers whose symptoms resolved in either less than $14$ days or more than $24$ days?

Show answer & explanation

Answer: 530

Answer

530

The standard deviation is the square root of the variance (

\sqrt{4} = 2

). The value

14

is two standard deviations below the mean (

18 - 2 \times 2 = 14

), which corresponds to the lower

2.5\%

tail of the normal distribution according to the empirical rule. The value

24

is three standard deviations above the mean (

18 + 3 \times 2 = 24

), which corresponds to the upper

0.15\%

tail. Summing these mutually exclusive probabilities gives

2.65\%

. Multiplying this by the cohort size of

20,000

yields exactly

530

individuals.

Step-by-Step Solution

Calculate the standard deviation

\sigma = 2

days

The standard deviation is required to apply the empirical rule, and it is the square root of the variance (

4

days

^2

Determine the standard score (z-score) limits

14

days corresponds to

z = -2

;

24

days corresponds to

z = +3

This establishes how many standard deviations the boundaries are from the mean of

18

Calculate tail probabilities

Lower tail probability is

2.5\%

; upper tail probability is

0.15\%

According to the 68-95-99.7 rule,

95\%

falls within

2

SDs (leaving

2.5\%

per tail), and

99.7\%

falls within

3

SDs (leaving

0.15\%

per tail).

Calculate total probability and expected count

530

workers

The total probability of

2.65\%

(

0.0265

) multiplied by the

20,000

cohort size yields

530

Key Concept

Applying the empirical (68-95-99.7) rule to a normal distribution using variance and standard deviation.

Estimated Time:1m 30s

Question 3640Question →

A maternal-fetal medicine research group is analyzing gestational age at delivery (in weeks) for all live births at a regional perinatal center over a five-year period. The dataset includes $12,500$ deliveries. The data show that the vast majority of deliveries occur at term, between $38$ and $41$ weeks of gestation. However, there is a long tail of premature deliveries extending down to $23$ weeks of gestation, with progressively decreasing frequency at earlier gestational ages. Which of the following correctly identifies the expected shape of this data distribution, the relationship between its mean and median, and the most appropriate measure of statistical dispersion to report?

Negatively skewed distribution; mean is less than median; interquartile range

Negatively skewed distribution; mean is greater than median; standard deviation

Positively skewed distribution; mean is greater than median; interquartile range

Positively skewed distribution; mean is less than median; standard deviation

Normal distribution; mean is equal to median; standard deviation

Show answer & explanation

Answer: Negatively skewed distribution; mean is less than median; interquartile range

Answer

Negatively skewed distribution; mean is less than median; interquartile range

The data has a long tail of smaller values (premature births down to

23

weeks) with the bulk of the data clustered at higher values (term births at

38

41

weeks). This asymmetric tail extending to the left defines a negatively skewed (left-skewed) distribution. In negatively skewed distributions, the extreme lower values disproportionately pull the mean to the left, making the mean less than the median. Because the data is not normally distributed, non-parametric summary measures are preferred; the interquartile range (IQR) is the most robust measure of dispersion because it is unaffected by extreme outliers in the tail.

Step-by-Step Solution

Identify the distribution shape from the description of the data spread.

The distribution has a peak at 38-41 weeks and a long tail extending leftwards down to 23 weeks, making it a negatively skewed (left-skewed) distribution.

Understanding the distribution shape is the first step in selecting appropriate descriptive statistics.

Evaluate how the negative skew affects the measures of central tendency.

The extreme low values in the left tail disproportionately pull the mathematical average down, causing the mean to be less than the median.

To determine the correct relationship between the mean and median for this specific distribution.

Determine the most robust measure of dispersion for skewed data.

The interquartile range (IQR) should be used because it measures the middle 50% of the data and is resistant to the extreme low values in the tail.

Standard deviation is inappropriate because it is highly sensitive to outliers and is intended for normally distributed data.

Key Concept

Effect of distribution skew on measures of central tendency and dispersion

PreviousPage 182 / 237Next

All practice questions

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Answer

Step-by-Step Solution

Key Concept